A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

This study is testing a new medication called belzutifan to see if it can effectively treat several rare types of tumors and genetic conditions. The goal is to see how well the medicine works at shrinking tumors that rely on a specific protein to grow in low-oxygen environments.

This trial is for adults (and some teenagers) who have been diagnosed with specific rare tumors or conditions, such as Von Hippel-Lindau disease or certain pancreatic or digestive tract cancers. You must also be in generally stable health, meaning you can swallow pills, have healthy heart function, and do not require supplemental oxygen.

Participants will take belzutifan, which is a pill designed to block a protein that helps cancer cells survive and multiply. Your medical team will monitor your progress closely to see how your tumors respond to the treatment and to keep you safe from any potential side effects.

The study is currently recruiting volunteers at locations in Los Angeles, California, and Chicago and Warrenville, Illinois. If you are interested, you should talk to your doctor to see if one of these centers is a good fit for you.